373 related articles for article (PubMed ID: 32936949)
1. Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection.
Burton MJ; Clarkson JE; Goulao B; Glenny AM; McBain AJ; Schilder AG; Webster KE; Worthington HV
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013626. PubMed ID: 32936949
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them.
Burton MJ; Clarkson JE; Goulao B; Glenny AM; McBain AJ; Schilder AG; Webster KE; Worthington HV
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013627. PubMed ID: 32936948
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial mouthwashes (gargling) and nasal sprays to protect healthcare workers when undertaking aerosol-generating procedures (AGPs) on patients without suspected or confirmed COVID-19 infection.
Burton MJ; Clarkson JE; Goulao B; Glenny AM; McBain AJ; Schilder AG; Webster KE; Worthington HV
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013628. PubMed ID: 32936947
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff.
Verbeek JH; Rajamaki B; Ijaz S; Sauni R; Toomey E; Blackwood B; Tikka C; Ruotsalainen JH; Kilinc Balci FS
Cochrane Database Syst Rev; 2020 May; 5(5):CD011621. PubMed ID: 32412096
[TBL] [Abstract][Full Text] [Related]
6. Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff.
Verbeek JH; Rajamaki B; Ijaz S; Sauni R; Toomey E; Blackwood B; Tikka C; Ruotsalainen JH; Kilinc Balci FS
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD011621. PubMed ID: 32293717
[TBL] [Abstract][Full Text] [Related]
7. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
8. Physical interventions to interrupt or reduce the spread of respiratory viruses.
Jefferson T; Del Mar CB; Dooley L; Ferroni E; Al-Ansary LA; Bawazeer GA; van Driel ML; Jones MA; Thorning S; Beller EM; Clark J; Hoffmann TC; Glasziou PP; Conly JM
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD006207. PubMed ID: 33215698
[TBL] [Abstract][Full Text] [Related]
9. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
10. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
[TBL] [Abstract][Full Text] [Related]
11. Saline irrigation for allergic rhinitis.
Head K; Snidvongs K; Glew S; Scadding G; Schilder AG; Philpott C; Hopkins C
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012597. PubMed ID: 29932206
[TBL] [Abstract][Full Text] [Related]
12. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.
Webster KE; O'Byrne L; MacKeith S; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD013877. PubMed ID: 36063364
[TBL] [Abstract][Full Text] [Related]
13. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
[TBL] [Abstract][Full Text] [Related]
14. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic.
Khan MM; Parab SR; Paranjape M
Am J Otolaryngol; 2020; 41(5):102618. PubMed ID: 32574894
[TBL] [Abstract][Full Text] [Related]
15. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
17. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
O'Byrne L; Webster KE; MacKeith S; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013876. PubMed ID: 34291813
[TBL] [Abstract][Full Text] [Related]
18. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
[TBL] [Abstract][Full Text] [Related]
19. Interventions to reduce contaminated aerosols produced during dental procedures for preventing infectious diseases.
Kumbargere Nagraj S; Eachempati P; Paisi M; Nasser M; Sivaramakrishnan G; Verbeek JH
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013686. PubMed ID: 33047816
[TBL] [Abstract][Full Text] [Related]
20. A quadruple blind, randomised controlled trial of gargling agents in reducing intraoral viral load among hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial.
Khan FR; Kazmi SMR; Iqbal NT; Iqbal J; Ali ST; Abbas SA
Trials; 2020 Sep; 21(1):785. PubMed ID: 32928313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
